Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Rhythm

“He said, ‘So, what about playing for me?’ I said, ‘Play what?’ He said, ‘Drums.’ I said, ‘Really? That would be so dope'”: The many drummers of Prince

We round up some of the Purple One's best sticksmen and women

MusicRadar

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity

Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat a rare form of obesity.

Investors Business Daily

Funds Go All In On Weight-Loss Leader; Stock Nears Highs

Rhythm stock is approaching its all-time high in a long base. Rhythm makes drugs to treat disorders due to genetic changes.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

NATIONAL SHOOTING TRIALS | Rhythm Sangwan pips Manu Bhaker to the top in sports pistol

Rhythm Sangwan beats Manu Bhaker 38-37 in National shooting selection trials; Akhil Sheoran tops men's rifle 3-position event.

The Hindu

Rhythm cafe gives Sunshine Coast people living with disability boost through employment

Two pastors turned baristas are helping change lives — one coffee at a time — at their Sunshine Coast cafe.

ABC News

Alan Kohler: Australia’s biotech sector has suddenly got much bigger

It wouldn’t take much of a nudge from the government to create a very vibrant and economically significant biotech industry.

The New Daily

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Rhythm Has Tripled In A Week And Quintupled Since May — Here's Why

Rhythm Pharmaceuticals has announced a steady drumbeat of good news for its obesity treatment, leading RYTM stock to triple in a week.

Investors Business Daily

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Rhythm Pharma Secures Non-Dilutive Financing Of $100M To Use Of This...

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners for a total investment of $100 million. Rhythm intends to use the proceeds to support global commercialization efforts for its newly approved Imcivree (setmelanotide) and ongoing clinical development. With this new approval, Imcivree is indicated for chronic weight management…

Benzinga

Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug

The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).

Benzinga

Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)

Benzinga

Thinking About Buying Stock In Lucid Group, Rhythm Pharmaceuticals Or Kohl's?

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Rhythm Pharmaceuticals Shares Are Falling Today

The FDA has extended the review period for Rhythm Pharmaceuticals Inc's (NASDAQ:RYTM) supplemental marketing application for Imcivree (setmelanotide) for obesity and control of hunger with Bardet-Biedl Syndrome (BBS) or Alström syndrome. The Prescription Drug User Fee Act (PDUFA) goal date has been revised to June 16, 2022, from March 16. FDA requested additional subgroup analyses…

Benzinga

Rhythm Pharma's Highlights Interim Setmelanotide Data In Long Term Genetic Disorder Trial

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) has

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

75 stories

KITE

56 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.